3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Completed
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Polyps
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Interventions
Fluorouracil
11
Leucovorin
10
Oxaliplatin
9
Bevacizumab
6
Irinotecan
5
Capecitabine
3
regorafenib
2
aflibercept
2
Folfox protocol
2
Exercise
2
Chemotherapy, Adjuvant
2
Cetuximab
2
Biopsy
2
Atorvastatin
2
tucatinib
1
trifluridine tipiracil drug combination
1
trastuzumab biosimilar HLX02
1
sulindac sulfone
1
sargramostim
1
retrovector encoding mutant anti-cyclin G1
1
poly ICLC
1
pidilizumab
1
pembrolizumab
1
p53 peptide 264-272, human
1
nilotinib
1
monalizumab
1
lonafarnib
1
irofulven
1
infigratinib
1
grp protein, Drosophila
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Colonic Neoplasms
×
eicosapentaenoic acid ethyl ester
×
Clear all
NCT03661047
2021-11-17
OMICC
Massachusetts General Hospital
Phase 2
Withdrawn